NHS Trusts Reject Palantir Patient Data Platform Over Limited Value
Multiple health bodies find Palantir’s £330m federated data platform redundant compared to existing local systems.
1Widespread Rejection of FDP
Numerous NHS trusts across England are actively rejecting Palantir’s £330m federated data platform. Freedom of information requests reveal that health leaders frequently find the system duplicative or retrograde. Many organizations report that existing local software already provides equivalent or superior functionality, leading them to decline adoption or revert to previous internal systems.
2Operational Value Concerns
Trusts like University Hospitals of North Midlands and Dorset HealthCare explicitly stated they have no plans to adopt the platform. Feedback indicates the software fails to offer significant improvements over current capabilities. Critics argue that the platform is not providing necessary value, questioning the efficacy of the central procurement strategy for health data.
3Political and Ethical Pressure
The government faces a critical decision regarding a break clause in the seven-year contract. Protests have intensified due to Palantir’s historical ties to the Israeli military and US homeland security. Public concern is further fueled by controversial remarks from cofounder Peter Thiel, who previously claimed the NHS makes people sick.
4Internal Resistance and Skepticism
Parliamentary select committees have urged the government to terminate the agreement, citing evidence that the system under-delivers. Liberal Democrat member Martin Wrigley noted that the responses justify concerns about the platform's quality. Activist groups like Medact argue that the government lacks any valid excuse to extend the contract given existing alternatives.
5Palantir’s Defense of Performance
Palantir dismisses the findings as slanted analysis, maintaining that the FDP is a successful program. The company highlights a green delivery rating and claims the platform has exceeded every target. They cite 117,000 additional operations and a 14.3% reduction in discharge delays as evidence of the system's positive impact on clinical efficiency.
6Data and Causality Caveats
NHS England has added a caveat to performance statistics, acknowledging that they cannot definitively draw conclusions about cause and effect. Because other variables remain uncontrolled, the direct impact of the platform on operational metrics remains debated. This uncertainty complicates the government's assessment of whether the platform truly drives better clinical outcomes.
7The Trust Factor Challenge
National data guardian Dr. Nicola Byrne has urged ministers to prioritize the trust factor in their decision-making. Over 44,000 individuals have filed legal objections regarding their data being stored in the platform. This widespread reluctance reflects a broader preference for local solutions over the centralized, controversial approach offered by the US firm.
8Future of NHS Procurement
The ongoing dispute highlights a fundamental tension between centralized tech procurement and local innovation. Critics advocate for developing interoperability standards rather than relying on a single vendor. As the government reviews the contract, the focus remains on whether the platform can prove its worth against a backdrop of significant institutional skepticism.